• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

Aastrom


  • Please log in to reply
150 replies to this topic

#1 caliban

  • Admin, Advisor, Director
  • 9,150 posts
  • 581
  • Location:UK

Posted 09 September 2009 - 06:58 PM


cell therapies

#2 caliban

  • Topic Starter
  • Admin, Advisor, Director
  • 9,150 posts
  • 581
  • Location:UK

Posted 09 September 2009 - 07:01 PM

Aastrom Shakes Up Management

Timothy Mayleben, a member of the board of Ann Arbor-based Aastrom Biosciences Inc. since 2005, has become the company's latest CEO.

He succeeds George Dunbar, who will become chairman of the board.

Both changes are to become effective after Aastrom's shareholder meeting, currently set for Dec. 14.

Dunbar had been president, CEO, CFO and a director. As board chairman, Dunbar will continue to advise the company on financial and strategic development initiatives.

Nelson M. Sims, who has served as chairman of the board since October 2008, is expected to assume the role of Lead Director.

Mayleben has stepped down from Aastrom's audit and compensation committees and Sims has been elected chair of the audit committee.

"These transitions position Aastrom to benefit from the expertise of some of the most experienced leaders working in life sciences today," Sims said.

Mayleben, 49, a member of the Aastrom board since June 2005, has been an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors since 2004. He reviously served as President, COO and a director of NightHawk Radiology Holdings Inc. Mayleben was formerly the COO and CFO of Esperion Therapeutics. He joined Esperion in 1998 and led the raising of more than $200 million in venture capital and institutional equity funding. He later negotiated the acquisition of Esperion by Pfizer in early 2004. Mayleben currently serves as a director for several private life science companies.

Dunbar, 63, joined Aastrom in July 2006 to advance the Company's TRC-based products through clinical, regulatory and market development. In May 2008, these activities were further strengthened when Mr. Dunbar focused the Company's clinical development programs on cardiovascular indications, including the U.S. Phase II IMPACT-DCM trial (dilated cardiomyopathy -- severe, chronic heart disease) and the U.S. Phase IIb RESTORE-CLI trial (critical limb ischemia). With experience over three decades that includes leadership positions at both large healthcare companies and early-stage life science companies, Dunbar will bring continuity to Aastrom's strategic direction and financing initiatives as chairman of the board.

Aastrom's proprietary Tissue Repair Cell technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. TRC-based products have been used in over 325 patients with over 10 years of positive safety data. The Company's ongoing development activities focus on applying TRC technology to cardiac and vascular tissue regeneration. The Company is currently focused on cardiovascular regeneration through a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia (CLI) patients (the RESTORE-CLI trial).

The company has long been in development stage and has little revenue. In its most recently reported quarter, the third fiscal quarter ended March 31, Aastrom reported a loss of $4 million or 3 cents a share on revenue of $58,000. That compares to a loss of $5 million or 4 cents a share on revenue of $202,000 a year earlier. For the nine months the loss was $12 million on $113,000 in revenue, vs. a year-earlier loss of $15.3 million on $373,000 in revenue.



#3 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 03 January 2011 - 01:48 PM

Biotech Sector Poised for Growth in 2011
Marketwire - Jan 3, 2011
NEW YORK, NY--(Marketwire - January 3, 2011) - Biotech companies have not been impervious to the economic downturn, but they have endured better than most. This is due in part to the fact that ...

View the full article

sponsored ad

  • Advert

#4 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 January 2011 - 03:15 PM

Drug Stocks In Focus (STJ, AVNR, ELN, ASTM)
Wall Street Bay - Jan 2, 2011
St. Jude Medical, Inc. (NYSE:STJ) slid 0.23% to $42.75. St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management ...

View the full article

#5 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 09 January 2011 - 06:57 PM

After presenting positive data, the transformation of Aastrom Biosciences continues
BioMedReports - Jan 9, 2011
To start off the year, they will be presenting Phase 2 Surgical-DCM 6-month results sometime this month, followed up by several(3-5) other key catalysts that investors should be looking for in ...
Aastrom Biosciences Inc (NASDAQ: ASTM) Posts Large Volume Increase, Hits $3.04 - American Banking News
Volume Spike Detected in Shares of Aastrom Biosciences as They Move Higher on 3.7x Above-Average Volume (ASTM) - Benzinga
Buzz Stocks

View the full article

#6 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 January 2011 - 01:19 PM

WATCH FOR AASTROM BIOSCIENCES TO POTENTIALLY PULLBACK AFTER GAINING 25.00% YESTERDAY (ASTM)
Zacks.com - 2 hours ago
Jan 11, 2011 (SmarTrend® News Watch via COMTEX) -- Aastrom Biosciences (NASDAQ:ASTM) traded in a range yesterday that spanned from a low of $2.65 to a high of $3.28. Yesterday, the shares gained ...

View the full article

#7 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 January 2011 - 12:56 PM

Sharp Percentage Gainers at NASDAQ are ACAD, HILL, ASTM, PSTI
Galaxy Stocks - 2 hours ago
ACAD percentage change reported the gain of 36.52% closed at $1.57 with the total traded volume of 10.27 million shares. Its market capitalization is $61.70 million. Company's 5 years revenue rate ...

View the full article

#8 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 January 2011 - 12:42 PM

NASDAQ Rallying Stock Updates: Aastrom Biosciences, NASDAQ:ASTM
Chart Poppers - 10 hours ago
Chartpoppers.com providing stock updates about NASDAQ rallying stock during last trading session. We will provide you a statistical and financial updates on Aastrom Biosciences, (NASDAQ:ASTM ...

View the full article

#9 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 13 January 2011 - 03:34 PM

3 Cheap Stocks in the News: SIFY, ASTM, JSDA
Tech24 - 1 hour ago
Sify Technologies Limited (NASDAQ: SIFY) is engaged in the business of providing e-comm and internet services. The company is mainly operational in India. The company also offers various ...

View the full article

#10 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 January 2011 - 01:30 PM

Aastrom Receives Key US Composition of Matter Patent for Autologous Cell Therapy
GlobeNewsWire - 2 hours ago
ANN ARBOR, Mich., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular ...

View the full article
  • dislike x 1

#11 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 January 2011 - 08:48 PM

Aastrom Phase II DCM Data Primer
The Market Financial - 1 hour ago
This Thursday, Aastrom Biosciences (ASTM) is scheduled to present interim phase II data on its tissue repair cell (TRC) therapy for dilated cardiomyopathy (DCM). In preparation of this event, I ...

View the full article

#12 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 20 January 2011 - 07:47 AM

Aastrom's expanded autologous cell therapy receives US patent
pharmabiz.com - 9 hours ago
Aastrom Biosciences, Inc. a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, announced that it has been granted a US patent which provides ...
Overview of Aastrom RESTORE-CLI and IMPACT-DCM Clinical Results Presented Today at the Conference on Cell Therapy for Cardiovascular Disease - TradersHuddle.com

View the full article

#13 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 20 January 2011 - 06:33 PM

Micro Cap Stocks Trading Lower (URRE, ASTM, ZLCS, MVIS)
Nothing But Buzz - 1 hour ago
The stock has average daily volume of 3.71 million shares. At current market price, the market capitalization of the company stands at $271.91 million. Aastrom Biosciences, Inc. (NASDAQ:ASTM ...
National Securities Analysts Downgrade Aastrom Biosciences Inc (NASDAQ: ASTM) to "Neutral" - American Consumer News

View the full article

#14 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 21 January 2011 - 12:01 PM

Poniard Pharmaceuticals New Year High Price - (PARD, ALTH, ASTM)
TapeBeat - 1 hour ago
PARD gain 12.90% with the closing price of $0.70. The overall volume in the last trading session was 4.29 million shares. Its fifty two week range was $0.35 - $2.70. The total market ...

View the full article

#15 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 21 January 2011 - 02:41 PM

NASDAQ Stock with Declining Trend Watchlist: Aastrom Biosciences, NASDAQ:ASTM
Chart Poppers - 2 hours ago
Aastrom Biosciences, (NASDAQ:ASTM) slumped 9.28% to close at $2.64, traded with the volume of 3.50 million shares while the market capitalization remained $74.58 million. Chartpoppers.com provides ...

View the full article

#16 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 24 January 2011 - 10:36 PM

Aastrom Biosciences, Inc. (NASDAQ: ASTM) Still Awaiting FDA
OTCEquity.com - 3 hours ago
In late October of 2010 Aastrom Biosciences (NASDAQ: ASTM) submitted an SPA to the Food and Drug Administration in regards to their Phase 3 trial for the treatment of Critical Limb Ischemia (CLI ...

View the full article

#17 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 26 January 2011 - 03:23 PM

Aastrom Biosciences, Inc. (NASDAQ:ASTM) maintains a Strong Working Capital Structure
Chart Poppers - 54 minutes ago
Aastrom Biosciences, Inc. (NASDAQ:ASTM) surged by 6.44% to close at $2.81 with overall traded volume of 2.26 million shares in the last trading day. The company maintains strong short term ...

View the full article

#18 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 26 January 2011 - 03:23 PM

Aastrom Biosciences, Inc. (NASDAQ:ASTM) maintains a Strong Working Capital Structure
Chart Poppers - 21 hours ago
Aastrom Biosciences, Inc. (NASDAQ:ASTM) surged by 6.44% to close at $2.81 with overall traded volume of 2.26 million shares in the last trading day. The company maintains strong short term ...

View the full article

#19 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 03 February 2011 - 03:27 PM

"Unconstitutional" Healthcare Reform Benefits StemCells & Aastrom Biosciences
Marketwire - 48 minutes ago
NEW YORK, NY--(Marketwire - February 3, 2011) - The healthcare sector received surprising news to start off the week when a federal judge in Florida became the second US judge to declare the ...

View the full article

#20 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 10 February 2011 - 08:44 PM

WBB Securities Analysts Begin Coverage on Aastrom Biosciences Inc (ASTM)
American Banking News - 3 hours ago
Equities research analysts at WBB Securities initiated coverage on shares of Aastrom Biosciences Inc (NASDAQ: ASTM) in a research note to investors on Wednesday. The analysts set a “sell” rating ...

View the full article

#21 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 February 2011 - 06:58 PM

Aastrom To Present At 2011 BIO CEO & Investor Conference
TheStreet.com - 2 hours ago
By GlobeNewswire 02/11/11 - 01:56 PM EST ANN ARBOR, Mich., Feb. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies ...
Aastrom to Present at 2011 BIO CEO & Investor Conference - Trading Markets

View the full article

#22 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 14 February 2011 - 09:38 PM

Aastrom Announces Restatement Of Historical Financial Results To Reflect Reclassification Of Warrants
TheStreet.com - 1 hour ago
By GlobeNewswire 02/14/11 - 04:30 PM EST ANN ARBOR, Mich., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced today that the company will be restating its ...

View the full article

#23 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 14 February 2011 - 09:30 PM


View the full article

#24 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 15 February 2011 - 02:19 PM

DIARY - U.S. Company Meetings for Tuesday, February 15, 2011
Reuters - 1 hour ago
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE GMT SYMBOL EVENT TITLE 15 Feb 0:00 (ZIXI.O) Zix Corp. at America's Growth Cap Emerging Growth Conf 15 Feb 7:30 (OPWV.O ...

View the full article

#25 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 February 2011 - 07:05 AM

Aastrom to Present at 2011 BIO CEO & Investor Conference
IEWY News - 7 minutes ago
ANN ARBOR, Mich., — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today ...

View the full article

#26 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 February 2011 - 04:34 PM

Webcast Alert: Aastrom To Report Fourth Quarter And Year-End 2010 Operating Results On February 28, 2011
TheStreet.com - 3 hours ago
By GlobeNewswire 02/22/11 - 11:30 AM EST ANN ARBOR, Mich., Feb. 22, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) will report operating results for the quarter and year ended ...

View the full article

#27 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 24 February 2011 - 11:34 PM

Aastrom Biosciences Inc. Reports Operating Results (10-Q/A)
GuruFocus.com - 41 minutes ago
Aastrom Biosciences Inc. has a market cap of $84.6 million; its shares were traded at around $2.19 with and P/S ratio of 950.2. Hedge Fund Gurus that owns ASTM: Steven Cohen of SAC Capital ...

View the full article

#28 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 25 February 2011 - 01:51 PM

RELATIVELY HIGH PRICE TO FORWARD SALES RATIO IN THE BIOTECHNOLOGY INDUSTRY DETECTED IN SHARES OF IMMUNOGEN (IMGN, GTXI, MITI, INO, ASTM)
Zacks.com - 3 hours ago
Feb 25, 2011 (SmarTrend® News Watch via COMTEX) -- Below are the five companies in the Biotechnology industry with the highest Price To Forward Sales ratios. The ratio shows how much Wall Street ...

View the full article

#29 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2011 - 02:16 PM

DIARY - U.S. Company Conference Call/Webcast for Feb 28, 2011
Reuters - 1 hour ago
DATE GMT SYMBOL COMPANY NAME AND PERIOD 28 Feb 13:00 (CSR) Q4 China Security & Surveillance Tech. Erngs Conf Call 28 Feb 13:30 (BPHX.O) Q4 BluePhoenix Solutions Ltd. Earnings Conf Call 28 Feb 13 ...

View the full article

#30 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2011 - 02:15 PM

DIARY - Non-S&P 500 Earnings for Monday, February 28, 2011
Reuters - 1 hour ago
ESTIMATE EST EPS 28 Feb BMO Q4 Almost Family (AFAM.O) 0.78 7 0.74 28 Feb AMC Q4 ALTRA HOLDINGS INC (AIMC.O) 0.22 6 0.14 28 Feb AMC Q4 AMYRIS INC (AMRS.O) -0.49 5 N/A 28 Feb BMO Q4 ALLIED NEVADA ...

View the full article




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users